Search research articles
Contact Us
Filters
Showing results (1-10 of 9) with videos related to
Page
of 1
Sort By:
Cytotherapy
|
December 13, 2022
A novel predictive algorithm to personalize autologous T-cell harvest for chimeric antigen receptor T-cell manufacture
Maeve A O'Reilly, Aman Malhi, Kathleen P L Cheok, et al.
Hemasphere
|
March 4, 2024
High pretreatment disease burden as a risk factor for infectious complications following CD19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma
Maeve A O'Reilly, Lorna Neill, Simon M Collin, et al.
Blood Cancer Journal
|
March 3, 2025
Risk factors for CAR T-cell manufacturing failure and patient outcomes in large B-cell lymphoma: a report from the UK National CAR T Panel
Vaishali Dulobdas, Amy A Kirkwood, Fabio Serpenti, et al.
Hemasphere
|
June 14, 2024
Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in the United Kingdom: A real-world intention-to-treat analysis
Maeve A O'Reilly, William Wilson, David Burns, et al.
Molecular Therapy. Advances
|
May 15, 2026
A comparison of two manufacturing methods in the phase I COBALT study of CD19CAR T for LBCL
Claire Roddie, Juliana Dias, Gordon Weng-Kit Cheung, et al.
British Journal of Haematology
|
March 8, 2026
Bridging practices prior to brexucabtagene autoleucel for mantle cell lymphoma in the United Kingdom: An analysis of modality, response, toxicity and survival
Maeve A O'Reilly, William Wilson, Bernard Maybury, et al.
Blood
|
February 23, 2023
Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed/refractory large B-cell lymphoma
Claire Roddie, Lazaros J Lekakis, Maria A V Marzolini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 31, 2021
Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
Claire Roddie, Juliana Dias, Maeve A O'Reilly, et al.
Blood Cancer Journal
|
April 15, 2024
Intention-to-treat outcomes utilising a stringent event definition in children and young people treated with tisagenlecleucel for r/r ALL through a national access scheme
Macarena Oporto Espuelas, Saskia Burridge, Amy A Kirkwood, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 9) with videos related to
Sort By:
Page
of 1
Cytotherapy
|
December 13, 2022
A novel predictive algorithm to personalize autologous T-cell harvest for chimeric antigen receptor T-cell manufacture
Maeve A O'Reilly, Aman Malhi, Kathleen P L Cheok, et al.
Hemasphere
|
March 4, 2024
High pretreatment disease burden as a risk factor for infectious complications following CD19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma
Maeve A O'Reilly, Lorna Neill, Simon M Collin, et al.
Blood Cancer Journal
|
March 3, 2025
Risk factors for CAR T-cell manufacturing failure and patient outcomes in large B-cell lymphoma: a report from the UK National CAR T Panel
Vaishali Dulobdas, Amy A Kirkwood, Fabio Serpenti, et al.
Hemasphere
|
June 14, 2024
Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in the United Kingdom: A real-world intention-to-treat analysis
Maeve A O'Reilly, William Wilson, David Burns, et al.
Molecular Therapy. Advances
|
May 15, 2026
A comparison of two manufacturing methods in the phase I COBALT study of CD19CAR T for LBCL
Claire Roddie, Juliana Dias, Gordon Weng-Kit Cheung, et al.
British Journal of Haematology
|
March 8, 2026
Bridging practices prior to brexucabtagene autoleucel for mantle cell lymphoma in the United Kingdom: An analysis of modality, response, toxicity and survival
Maeve A O'Reilly, William Wilson, Bernard Maybury, et al.
Blood
|
February 23, 2023
Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed/refractory large B-cell lymphoma
Claire Roddie, Lazaros J Lekakis, Maria A V Marzolini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 31, 2021
Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
Claire Roddie, Juliana Dias, Maeve A O'Reilly, et al.
Blood Cancer Journal
|
April 15, 2024
Intention-to-treat outcomes utilising a stringent event definition in children and young people treated with tisagenlecleucel for r/r ALL through a national access scheme
Macarena Oporto Espuelas, Saskia Burridge, Amy A Kirkwood, et al.
Page
of 1